Heterozygous germ-line mutations of BMPR2 are the major contributor to familial clustering of pulmonary arterial hypertension (PAH). To further explore the genetic basis of PAH in isolated cases we undertook a candidate gene analysis to identify potentially deleterious variation.
2 PAH (MIM# 178600) is a progressive vascular disorder often fatal as a result of right heart failure [Humbert et al., 2010] . Mutations of BMPR2 (MIM# 600799), encoding a bone morphogenetic type II receptor of the TGF-β family, are the major genetic determinant in familial PAH (FPAH). Idiopathic PAH (IPAH), defined as arising spontaneously in the absence of a recorded family history of disease, is indistinguishable from the familial form [Machado et al., 2009] . The detection of germ-line BMPR2 mutation in ~25% of IPAH cases, posing hereditary risk to offspring, has led to the re-classification of mutation carriers as heritable PAH (HPAH) [Deng et al., 2000; Lane et al., 2000; Machado et al., 2009] . Over 70% of HPAH mutations predict premature truncation likely leading to transcript loss via the nonsense-mediated decay (NMD) pathway [Machado et al., 2009] . Deleterious BMPR2 mutation in the IPAH population indicates a genetic basis to disease and suggests the existence of additional genetic and/or environmental factors in PAH pathogenesis yet to be fully annotated. Indeed, rare disease alleles of the TGF-β receptors, ALK1 (MIM# 601284) and endoglin (MIM# 131195) , and members of the SMAD family have recently been shown to underlie susceptibility to HHT and pulmonary hypertension [Harrison et al., 2005; Shintani et al., 2009] . BMPR-II triggers signal transduction through the receptor SMADs (R-SMADs) 1, 5 and 9, upon ligand binding and complex formation with a type I receptor, namely BMPR-1A, -1B or ALK1. R-SMADs translocate to the nucleus in complex with co-SMAD4 to regulate transcription of target genes, a process dependent on the presence of a conserved proximal DNA binding MH1 domain and a trans-activating MH2 domain [Massague et al., 2000] . As impaired responses to BMP-specific SMADs are acknowledged as critical in the development of PAH [Nishihara et al., 2002; Rudarakanchana et al., 2002] , we sought to assess the genetic contribution of this pathway to disease susceptibility by conducting an extensive survey of a large PAH cohort, excluded for BMPR2 mutation. Here we report the identification of four gene defects in SMAD1 (MIM# 601595), SMAD4 (MIM# 600993) and SMAD9 (MIM# 603295). Functional analyses suggest significant, albeit limited consequences on transcript integrity, signaling and target gene regulation.
Ethical approval for these studies was obtained by local ethical committees and all patients provided informed consent. A diagnosis of PAH was confirmed as described previously [Machado et al., 2009] . The European IPAH cohort comprised a total of 158 subjects ascertained by specialist UK and European centers and displayed a gender bias favoring females (1.9:1). The PAH panel with associated disease (APAH) (n=136) comprised cases with HIV infection (n=9), portal hypertension (n=11), congenital heart disease (n=15), thromboembolic disease (n=42) and connective tissue disease (n=59). Japanese IPAH subjects (n=30) were ascertained through a single specialist referral centre. All patients had been screened for BMPR2 mutation by direct sequencing and/or DHPLC employing primer sets previously described [Machado et al., 2001] .
Direct sequencing was performed on ABI377 fragment analyzer. DHPLC was performed using Several known polymorphisms but no putative mutations were identified in the APAH samples.
Screening of SMAD1 in the IPAH patient series revealed a novel missense variant (c.8T>C, p.V3A) within exon 1, upstream of the MH1 domain (Fig. 1A) . Within SMAD4 two defects were identified in independent IPAH cases, namely a predicted splice-site mutation (c.1448-6T>C)
upstream of the terminal exon 11 and a missense variant (c.38A>G, p.N13S) (Fig. 1A-C) . A novel missense variant, (c.127A>G, p.K43E), was observed in a patient of Japanese origin in SMAD9 impacting upon the MH1 domain (Fig. 1A) . The lack of parental material precluded a determination of whether identified variants were de novo. All variants were absent in 960
European control samples and an additional 284 French control samples. The SMAD9 variant was further excluded from a panel of 340 Japanese controls. Of note, the identified variants were absent from the 1000 Genomes database and an in-house repository of 60 exome sequenced control samples. All three of the substituted amino acid residues detected in SMADs 1, 4 and 9 5 were highly conserved through evolution, to the level of Takifugu rubripes (Fig. 1D ). High degrees of conservation have traditionally been considered to be a measure of the potential importance of amino acid residues to protein function. The clinical features of the subjects harboring potential disease causing variation within SMAD genes are presented in Supp. Table   S1 . To investigate the impact of the missense variants on SMAD mediated signaling, we adapted a SMAD reporter assay to be selective to BMP stimulation [Nasim et al., 2008] (Supp. Fig. S1 ).
Wild type constructs for SMADs 1 and 4 activated reporter activity as anticipated (Supp. Fig.   S1 ). Over-expression of the SMAD1 variant generated reduced basal activity by comparison to wild type and impaired responses to ligand stimulation ( Fig. 2A and B) . The SMAD9 p.K43E
construct also displayed reduced reporter activity when compared to wild type (Fig. 2C) , a diminished response to BMPR-II over-expression (Fig. 2C ) and stimulation by BMP4 and BMP9 ligands (Fig. 2D ). No difference in the level of activation was seen between the wild type and missense SMAD4 constructs either in the absence or presence of ligand ( Fig. 2A and data not shown) which may indicate subtle effects on function not detectable by this reporter system or the possibility that this is an extremely rare population variant with no impact on PAH susceptibility.
Notably, this impaired activity was modest relative to classical, functionally null BMPR-II substitutions underlying familial and hereditary PAH [Nasim et al., 2008] . In silico analysis of the c.1448-6T>C variant predicted impaired splicing compared to wild-type [Nalla and Rogan, 2005] . By quantitative RT-PCR analyses, we observed a putative reduction in transcript level of the c.1448-6T>C variant in patient derived leukocytes compared to the wild type; however, due to the known variability of mRNA expression in leucocytes this finding was treated as indicative (Supp. Fig. 2D ). To investigate this observation further we performed RT-PCR on these samples and excluded the existence of aberrant splice products thereby indicating pre-mRNA splicing was preserved (Supp. Fig. S2A and B) and the NMD surveillance machinery likely not activated 6 although in the absence of a patient cell line formal exclusion of this process could not be confirmed. We next questioned whether the reduction in SMAD4 transcript level might be explained by an alteration in splicing efficiency. Using an assay of splicing competency (Supp. Fig. 2C ) [Nasim et al., 2002] , we observed a significant reduction in reporter activity for the variant construct relative to wild type, consistent with a decrease in splicing efficiency (Fig. 2E ).
Both SMAD4 variants were distinct to mutations observed in HHT alone and JP-HHT, the majority of which cluster in the MH2 domain encoded by exons 8-11 [Gallione et al., 2006; Iyer et al., 2010] . Unusually, these variants represent the most proximal amino acid substitution and only defective splice allele associated with vascular disease but the present data set is insufficient to draw meaningful correlations with phenotype. To better elucidate the functional significance of SMAD mutations in PAH, we assessed the expression of the Id2 gene in pulmonary artery smooth muscle cells (PASMCs) heterozygous for the SMAD9 mutation p.K43E, derived from explant lung taken at transplantation which exhibited extensive pulmonary vascular remodeling (Supp. Fig S3) . The Id2 transcript, a downstream target of BMP and TGF-β signaling was significantly reduced in the SMAD9 variant cell line comparative to WT PASMC although responses to ligand were largely preserved (Fig. 2F) . A similar level of reduction of Id2 transcript expression was observed in a PAH cell line with a previously identified, pathogenic BMPR2 mutation (p.W9X) (Suppl. Fig S4) . Western blotting and immunofluorescence revealed no differences in protein stability and subcellular localization between WT and missense constructs of SMADs 1, 4 and 9 (Supp. Fig S5) , suggesting that variant proteins were likely to be present and intact in the cell. In light of the moderate effect size of these variants it is plausible that they may require one or more genetic or environmental triggers to precipitate disease. Alternatively it remains feasible that they may more substantially perturb one or more of the newly emerging SMAD-independent pathways. The systematic analysis of the BMP-specific SMAD family in 7 large patient cohorts is of central importance in determining the genetic contribution of this pathway, vital in maintenance of the pulmonary vasculature, to the pathogenesis of PAH. The low frequency of potentially pathogenic variation in genes encoding SMAD mediators of BMP would suggest that SMAD mutation makes a small contribution to inherited genetic susceptibility to I/APAH. The application of recent technological advances in high-throughput sequencing of coding and whole genomes may prove effective in gaining a fuller understanding of the genetic factors contributing to PAH, providing an opportunity for rapid advances in the understanding of the molecular mechanisms underlying this disorder.
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